19.22 - 22
15.68 - 32.09
Join Discuss about XOMA with like-minded investors
Next Dividend Date
XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA's pioneering efforts in the discovery and development of antibody therapeutics. The Company's royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.
CEO: James Neal
HQ: 2200 Powell St Ste 310 Emeryville, 94608-1818 California